Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what arrangements his Department plans to put in place for new patients who wish to access drugs included in the Risk Sharing Scheme for the supply of disease modifying treatments for multiple sclerosis, glatiramer acetate and beta interferon after funding for that scheme ceases.

Colleagues are in discussion with NHS England colleagues to plan for a smooth transition from the end of the Scheme in England, and with colleagues in the Devolved Administrations in respect of Multiple Sclerosis services in their countries.